- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.10. | OKYO Pharma to Present at BIO-Europe 2025 in Vienna | 235 | GlobeNewswire (Europe) | LONDON and NEW YORK, Oct. 29, 2025), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA... ► Artikel lesen | |
| 29.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.10. | Insider-Kauf bei OKYO Pharma: Gesellschaft des Executive Chairman erwirbt 210.000 Aktien an der NASDAQ | 3 | Investing.com Deutsch | ||
| 16.10. | OKYO Pharma Announces Chairman and Founder Acquires Shares | 213 | GlobeNewswire (Europe) | LONDON and NEW YORK, Oct. 16, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 16.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 23.09. | OKYO Pharma: H.C. Wainwright bestätigt Kaufempfehlung nach Ankündigung neuer klinischer Studie | 2 | Investing.com Deutsch | ||
| 23.09. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on clinical trial plans | 1 | Investing.com | ||
| 22.09. | OKYO Pharma advances urcosimod to next clinical trial for eye pain | 4 | Investing.com | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 22.09. | OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain | 199 | GlobeNewswire (Europe) | LONDON and NEW YORK, Sept. 22, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 22.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.07. | OKYO Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 4 | SEC Filings | ||
| 17.07. | OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain | 345 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 17, 2025), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic... ► Artikel lesen | |
| 17.07. | OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data | 2 | Investing.com | ||
| 16.07. | OKYO Pharma Stock Rises 8% On Positive Phase 2 Trial Results For Neuropathic Corneal Pain Therapy | 3 | RTTNews | ||
| 16.07. | OKYO Pharma reports results from Urcosimod trial | 2 | Seeking Alpha | ||
| 16.07. | OKYO Pharma meldet positive Top-Line-Ergebnisse aus Phase-2-Studie mit Urcosimod | - | Investing.com Deutsch | ||
| 16.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.07. | OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain | 210 | GlobeNewswire (Europe) | After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating... ► Artikel lesen | |
| 16.07. | Positive Studiendaten zu Augenschmerzmittel beflügeln OKYO-Pharma-Aktie | 1 | Investing.com Deutsch | ||
| 16.07. | OKYO Pharma stock surges after positive Phase 2 results for eye pain drug | 2 | Investing.com |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 598,60 | +0,84 % | IDEXX LABORATORIES INC /DE - 8-K, Current Report | ||
| BIOXCEL THERAPEUTICS | 1,416 | +0,57 % | BioXcel Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| ADAPTIMMUNE THERAPEUTICS | 0,025 | +25,00 % | Adaptimmune Therapeutics PLC - 15-12G, Securities registration termination | ||
| VOYAGER THERAPEUTICS | 3,470 | +2,42 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 3,183 | +1,47 % | Anavex Life Sciences Corp.: Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease | Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company's Alzheimer's Disease clinical trial results NEW... ► Artikel lesen | |
| CELLAVISION | 14,440 | +0,98 % | CellaVision: Softer Quarter with Mixed Regional Performance | Organic sales growth:Q3, 2025: 2.6% (9.4)EBITDA margin:Q3, 2025: 28% (27)July 1st - September 30th, 2025Net sales decreased by -1.7% (6.4) to SEK 176 m (179).Sales increased organically by 2.6% (9.4)... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 5,200 | +1,96 % | Precision BioSciences launches $75M stock and warrant offering | ||
| ZYMEWORKS | 15,900 | -0,62 % | Zymeworks Inc.: Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-? at AACR-NCI-EORTC Conference | Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung... ► Artikel lesen | |
| VTV THERAPEUTICS | 26,200 | +2,34 % | vTv Therapeutics Inc.: vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 12,850 | +13,72 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies | Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,790 | +0,84 % | Neuphoria Therapeutics, Inc.: Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value | Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fund LP No Stockholder Action Required at This Time BURLINGTON, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| NUVATION BIO | 4,855 | +3,63 % | Nuvation Bio to Participate in Upcoming Investor Conferences | Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief... ► Artikel lesen | |
| MIRA PHARMACEUTICALS | 1,090 | -6,03 % | MIRA PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
| PLIANT THERAPEUTICS | 1,530 | +5,52 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE... ► Artikel lesen | |
| ONCONETIX | 2,360 | -9,23 % | Onconetix, Inc. - 10-Q, Quarterly Report |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,255 Euro und damit -6,43 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.